JHEP Reports

Article	Citations
Trans-splenic anterograde coil assisted transvenous obliteration versus retrograde transvenous obliteration: are we heading the right way?	146
Editorial Board page	146
Editorial Board page	117
Statins in MASLD: Challenges and Future	113
Applications of the AI-Cirrhosis-ECG (ACE) score for improving prediction of decompensation and liver-related outcomes in cirrhosis: A multi-cohort study	102
Associations between fruit and vegetable consumption and HCC occurrence in patients with liver cirrhosis	101
Response to: McKiernan P, Bernabeu JQ, Girard M, et al. Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis. JHEP Rep 2023; 6:100949	99
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data	95
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation	88
Protective Role of Physical Activity Against HCC Risk in Type 2 Diabetes: Evidence and Public Health Perspectives	73
Surveillance for hepatocellular carcinoma in patients with Primary Biliary Cholangitis: for all or just for some?	71
Serum FGF21 as predictor of response to atezolizumab and bevacizumab in HCC	66
Macrophage ATG16L1 promotes liver regeneration after partial hepatectomy	65
Multicenter Evaluation of Abbreviated MRI and Ultrasound for Detecting Early-Stage Hepatocellular Carcinoma	64
Editorial Board page	60
Copyright and information	54
Contents	53
Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis	53
Social support and risk of mortality in cirrhosis: A cohort study	50
Platelet-derived thrombospondin 1 promotes immune cell liver infiltration and exacerbates diet-induced steatohepatitis	48
Copyright and information	47
Prophylactic blood product transfusions in post-endoscopic band ligation bleeding – ‘tag in TEG’	46
Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study	45
A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice	45
Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma	44

Molecular magnetic resonance imaging of liver inflammation using an oxidatively activated probe	44
Copyright and information	43
Editorial Board page	43
Contents	42
Reply to: “Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans”	42
Fructoholism in adults: The importance of personalised care in metabolic dysfunction-associated fatty liver disease	41
Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma	40
The third year	40
Comment on “Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review”	39
Hyperammonaemia induces mitochondrial dysfunction and neuronal cell death	39
Contents	39
Copyright and information	38
Editorial Board page	37
Copyright and information	37
Contents	37
Editorial Board page	36
Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag	34
Increased carbohydrate deficient transferrin: Whisky or candy?	34
Editorial Board page	34
Copyright and information	34
Contents	34
Copyright and information	33
Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH	33
Editorial Board page	32
Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure	32
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes	31
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis	31
Predicting post-resection recurrence by integrating imaging-based surrogates of distinct vascular patterns of hepatocellular carcinoma	31
Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma	30
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV	29
AlcoChange: A digital therapeutic for patients with alcohol-related liver disease	29
A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications	29
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice	29
Sex differences in chronic liver disease and benign liver lesions	29
Paediatric hepatocellular adenomas: Lessons from a systematic review of relevant literature	28
High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia	28
The potential of volatile organic compounds to diagnose primary sclerosing cholangitis	28
Development of mutated β-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC	28
Immunomodulatory receptor VSIG4 is released during spontaneous bacterial peritonitis and predicts short-term mortality	27
Circulating neutrophil anti-pathogen dysfunction in cirrhosis	27
Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection	27
Reply to: “The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites”	27
Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status	27
Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2 mouse	26
A small animal model of chronic hepatitis E infection using immunocompromised rats	26
Epigenetics of alcohol-related liver diseases	26
Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma	26
Characterisation of forkhead box protein A3 as a key transcription factor for hepatocyte regeneration	26
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis	25
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants	25

MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis	25
Predicting overt hepatic encephalopathy after TIPS: Value of three minimal hepatic encephalopathy tests	25
Trends in hepatocellular carcinoma stage by racial/ethnic group in the United States, 1992–2019	25
CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment	25
Hepatic estrogen receptor alpha drives masculinization in post-menopausal women with metabolic dysfunction-associated steatotic liver disease	24
Risk of hepatocellular carcinoma in Asian patients with primary biliary cholangitis: A nationwide and hospital cohort study	24
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis	23
Odevixibat treatment in an adult patient with advanced icteric progressive cholestatic liver disease	23
ZBTB20 regulates WNT/CTNNB1 signalling pathway by suppressing PPARG during hepatocellular carcinoma tumourigenesis	23
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort	23
Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid	23
Editorial Board page	22
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool	22
Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component	22
Assessing the impact of COVID-19 on liver cancer management (CERO-19)	22
Transcriptomic landscapes of effective and failed liver regeneration in humans	22
Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease	22
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis	22
Liver transplant selection criteria and outcomes in critically ill patients with ACLF	21
Contents	21
ABCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome	21
Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada	20
Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging	20
Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease	20
Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis	20
Malignant transformation of hepatocellular adenoma	20
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV	20
Editorial Board page	19
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]	19
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication	19
Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis	19
Virological markers for clinical trials in chronic viral hepatitis	19
Contents	19
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	19
Gut dysbiosis as a driver in alcohol-induced liver injury	19
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study	19
Essential roles of B cell subsets in the progression of MASLD and HCC	18
Editorial Board page	18
Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy	18
Liver transplantation for HBV-related liver disease: Impact of prophylaxis for HBV on HCC recurrence	18
Lipid metabolism in MASLD and MASH: From mechanism to the clinic	18
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: a challenge for surveillance?	18
Hepatitis D virus infection triggers CXCL9-11 upregulation in hepatocytes and liver infiltration of CXCR3+ CD4 T cells	18
Tumor organoids for primary liver cancers: A systematic review of current applications in diagnostics, disease modeling, and drug screening	18
Prediction of long-term HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients	18
Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma	18
CRISPR/Cas9 gene therapy increases the risk of tumorigenesis in the mouse model of hereditary tyrosinemia type I	17
Waiting time dictates impact of frailty: A Spanish multicenter prospective study	17
Direct mechanical exposure initiates hepatocyte proliferation	17
Loss of hepatic FTCD promotes lipid accumulation and hepatocarcinogenesis by upregulating PPARγ and SREBP2	17
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer	17
Predicting liver ablation volumes with real-time MRI thermometry	17
Environmental exposures are important risk factors for advanced liver fibrosis in African American adults	17
Circulating complement factor H levels are associated with disease severity and relapse in autoimmune hepatitis	17
Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease	17
Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease	17
New targets for NAFLD	16
Case-finding strategies in non-alcoholic fatty liver disease	16
Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults	16
The Weight of Choices: Prioritizing Lifestyle Over GLP-1 Receptor Agonist Therapy in Managing MASLD	16
Mechanobiology of portal hypertension	16
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B	15
Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake	15
Liver fibrosis screening increases alcohol abstinence	15
Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates	15
Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors	15
Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease	15
Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion	15
Burden, risk factors, and outcomes of multidrug-resistant bacterial colonisation at multiple sites in patients with cirrhosis	15
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD	15
Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis	15
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	15
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st	14
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort	14
Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event	14
Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation	14
Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies	14
International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria	14
Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis	14
Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency	14

Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation	14
Emerging roles of circular RNAs in liver cancer	14
Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis	14
The dual role of TIGIT in regulatory and effector T cells in chronic liver disease	14
Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency	13
Antagonism between wild-type and mutant β-catenin controls hepatoblastoma differentiation via fascin-1	13
Contents	13
Copyright and information	13
Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system	13
Editorial Board page	13
Response to: “Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC”	13
Editorial Board page	13
A personalized approach for tumour biopsy in hepatocellular carcinoma	13
Copyright and information	13
Contents	13
Blue-collar work is a risk factor for developing IgG4-related disease of the biliary tract and pancreas	12
Reply to: “Comment on “Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review””	12
Copyright and information	12
Editorial Board page	12
Contents	12
Top level research in hepatology: COVID-19 and beyond	12
Editorial Board page	12
Deep Learning Empowered Gadolinium-Free Contrast-Enhanced Abbreviated MRI for Diagnosing Hepatocellular Carcinoma	12
Editorial Board page	11
Deep phenotyping of patients with MASLD upon high-intensity interval training	11
Editorial Board page	11
Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival.	11
Arachidonic acid activates NLRP3 inflammasome in MDSCs via FATP2 to promote post-transplant tumour recurrence in steatotic liver grafts	11
Contents	11
Identification and clinical implications of endogenous retrovirus elements suppressed by SETDB1 in hepatocellular carcinoma	11
Cirrhosis-related sarcopenia may not resolve after liver transplantation	11
Diversity and inclusion in chronic hepatitis B randomised controlled trials: A systematic meta-epidemiological review	11
Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC	11
Copyright and information	11
Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome	11
Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts	11
Proinflammatory Macrophages Release CXCL5 to Regulate T Cell Function and Limit Effects of αPD-1 in Steatosis-driven Liver Cancer	11
Introduction to corrigendum to ‘Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis’ [JHEP Reports 3 (2021) 100287]	10
Ketamine restriction correlates with reduced cholestatic liver injury and improved outcomes in critically ill patients with burn injury	10
Copyright and information	10
Reply to: “Challenges in the diagnosis and management of AIH-PBC syndrome”	10
A novel in vitro system for simultaneous infections with Hepatitis B, C, D and E Viruses	10
Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment	10
Copyright and information	10
Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)	10
ALDH1L2 drives HCC progression through TAM polarization	10
Decreased maximal cortisol secretion rate in patients with cirrhosis: Relation to disease severity	10
Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)	10
Editorial Board page	10
Contents	10
Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy	10
Editorial Board page	10
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV	10
Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis	9
Defatting strategies in the current era of liver steatosis	9
Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis	9
Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide	9
A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection	9
A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice	9
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study	9
Hepatic decompensation is accelerated in patients with cirrhosis and alpha-1 antitrypsin Pi∗MZ genotype	9
Reply to: “Does currently recommended maternal antiviral prophylaxis against mother-to-child transmission of hepatitis B virus require enhancement?”	9
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection	9
Platelet adhesion assessed by PFA-100 is not linked to progression of ACLD	8
Maternal obesity increases the risk of hepatocellular carcinoma through the transmission of an altered gut microbiome	8
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial	8
SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH	8
Copyright and information	8
Ductular reaction is a prognostic factor in primary biliary cholangitis	8
Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease	8
Hepatopulmonary syndrome in patients with porto-sinusoidal vascular disorder: Characteristics and outcome	8
A gut microbiota-independent mechanism shapes the bile acid pool in mice with MASH	8
Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly	8
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022	8
Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure	8
Reply to: “Ductular reaction is a prognostic factor in primary biliary cholangitis”	8
Potential role of liver-resident CD3+ macrophages in HBV clearance in a mouse hepatitis B model	8
Association of physical activity, including amount and maintenance, with the risk of HCC among patients with type 2 diabetes	8
MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma	8
Downregulation of hepatic METTL3 contributes to APAP-induced liver injury in mice	8
Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines	8
Cellular origins of regenerating liver and hepatocellular carcinoma	8
Contents	8
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma	8
Aetiology of acute hepatitis of unknown in children, association with AAV2 and controversies	8